Positron is a nuclear medicine healthcare company specializing in the business of cardiac Positron Emission Tomography PET . Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease CAD , a leading cause of death in the United States. Positron s products and services empower healthcare providers to more accurately diagnose CAD and improve patient outcomes while practicing cost effective medicine. Positron, a pioneer in nuclear cardiology for over years, is establishing a unique position by vertically integrating the fragmented and limited supply environment that exists in the cardiac PET marketplace today. Positron s approach is to provide nuclear cardiologists an end to end solution by offering award winning imaging technology, clinical services, imaging agents and innovative financing packages conveniently from a single source. Positron s approach in securing the cardiac PET supply chain will bring substantial advantages in accelerating the adoption of this superior modality and growth of the nuclear cardiology industry.
Quote | Positron Corp (OTCMKTS:POSC)
Last: | $1.22 |
---|---|
Change Percent: | 0.0% |
Open: | $1.22 |
Close: | $1.22 |
High: | $1.22 |
Low: | $1.22 |
Volume: | 482 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Positron Corp (OTCMKTS:POSC)
Niagara Falls, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular ...
Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity™ PET-C...
Message Board Posts | Positron Corp (OTCMKTS:POSC)
Subject | By | Source | When |
---|---|---|---|
Incredible news. Positron will complete the 510K FDA | docteur/scanner | investorshub | 03/01/2023 2:58:48 PM |
posc | srinsocal | investorshub | 02/04/2023 6:23:49 PM |
Lantheus F18 studies look great. Expectations should be | Medtrade77 | investorshub | 09/15/2022 1:32:07 PM |
Approval of Flurpiridaz to be announced in September. | Medtrade77 | investorshub | 08/16/2022 5:32:51 PM |
$POSC Positron Corporation Announces Key Sales & Services | Thugmuffin | investorshub | 06/27/2022 2:08:55 PM |
News, Short Squeeze, Breakout and More Instantly...
Niagara Falls, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular ...
Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity™ PET-C...
Niagara Falls, NY, July 31, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company that manufactures, sells and services PET imaging systems and clinical services, is pleased to announ...